POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
January 12, 2023 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
January 11, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Oncology Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2029
January 11, 2023 07:55 ET
|
Fortune Business Insights
Pune, India, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The market size for Oncology Molecular Diagnostics is expected to be large and growing due to increasing incidences of cancer and the use of...
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
January 11, 2023 02:00 ET
|
Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Novotech Acquires European CRO – Strengthens Global Operations
January 09, 2023 11:33 ET
|
Novotech
SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
January 09, 2023 10:33 ET
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
January 09, 2023 07:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer
January 09, 2023 07:00 ET
|
Ractigen Therapeutics
SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...
Health Care Consulting Leader Monument Analytics Will Change Its Name to Stage Analytics™
January 05, 2023 09:00 ET
|
Stage Analytics™
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Health care consulting leader Monument Analytics announces that it has changed its name to Stage Analytics™. The new name captures the importance of...
Persbericht Biocartis Group NV: Openbaarmaking van transparantiekennisgevingen
January 04, 2023 11:40 ET
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE4 januari 2023, 17:40 CET Openbaarmaking van transparantiekennisgevingen Mechelen, België, 4 januari 2023 – Biocartis Group NV (de ‘Vennootschap’...